UPDATE: BTIG Starts BioAtla Inc. (BCAB) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St futures recover as oil slides ahead of inflation test
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- S&P 500, Dow futures attempt recovery ahead of inflation report
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
UPDATE: Credit Suisse Starts BioAtla Inc. (BCAB) at Outperform
January 11, 2021 5:01 AM EST(Updated - January 11, 2021 6:23 AM EST)
Credit Suisse analyst Tiago Fauth initiates coverage on BioAtla Inc. (NASDAQ: BCAB) with a Outperform rating and a price target of $49.00.
The analyst comments "The companys two lead proprietary programs targeting AXL (BA3011) and ROR2 (BA3021) are antibody-drug conjugates (ADC) designed with BCABs proprietary conditionally active biologics (CAB) technology. CAB molecules have... More
UPDATE: Jefferies Starts BioAtla Inc. (BCAB) at Buy Ahead of Two Separate Phase 2 Readouts
January 11, 2021 4:43 AM EST(Updated - January 11, 2021 8:52 AM EST)
Jefferies analyst Biren Amin initiates coverage on BioAtla Inc. (NASDAQ: BCAB) with a Buy rating and a price target of $51.00 ahead of Ph2 interim readouts in H2' 21. Jefferies was joint book-running manager in BCAB's... More
JPMorgan Starts BioAtla Inc. (BCAB) at Overweight
January 11, 2021 4:42 AM ESTJPMorgan initiates coverage on BioAtla Inc. (NASDAQ: BCAB) with a Overweight rating and a price target of $45.00.
For an analyst ratings summary and ratings history on BioAtla Inc. click here. For more ratings news on BioAtla Inc. click here.
Shares of BioAtla Inc. closed at $38.25 yesterday.
... More